

VIEWPOINTS

Antibacterial mass drug administration for child mortality reduction: Opportunities, concerns, and possible next steps

Isaac I. Bogoch^{1,2*}, Jürg Utzinger^{3,4}, Nathan C. Lo^{5,6}, Jason R. Andrews⁵


1 Divisions of General Internal Medicine and Infectious Diseases, Toronto General Hospital, University Health Network, Toronto, Canada, **2** Department of Medicine, University of Toronto, Toronto, Canada, **3** Swiss Tropical and Public Health Institute, Basel, Switzerland, **4** University of Basel, Basel, Switzerland, **5** Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, United States of America, **6** Division of Epidemiology, Stanford University School of Medicine, Stanford, California, United States of America

* isaac.bogoch@uhn.ca

Mass drug administration (MDA) campaigns are designed to empirically treat at-risk populations for neglected tropical diseases caused by infections with bacteria (e.g., trachoma) and parasites (e.g., schistosomiasis and soil-transmitted helminthiasis) in a defined geographic region. Decisions to initiate treatment in communities are often made based on predefined prevalence thresholds, but once treatment is undertaken, it is typically provided to all individuals of certain age groups (e.g., school-age children or all community members aged 5 years and above) without individual diagnosis. Such campaigns are a hallmark of neglected tropical disease control and elimination in low- and middle-income countries (LMICs) [1, 2]. Recent success stories include considerable reductions in the global incidence of lymphatic filariasis [3], onchocerciasis [4], and trachoma [5] through MDA programs, as well as reduction in the prevalence and intensity of soil-transmitted helminth infection and schistosomiasis [6, 7].

A recent cluster-randomized trial conducted in Malawi, Niger, and Tanzania revealed that twice-annual MDA with azithromycin for children aged 1–59 months reduced all-cause mortality by approximately 14% [8]. A major distinction between this study and prior MDA efforts is that the treatment was not targeted to particular pathogens but rather was trialed on the basis of beneficial, unintended effects that were seen in the context of earlier azithromycin MDA programs for trachoma [9, 10]. Although the specific mechanisms for mortality reduction have yet to be elucidated, it is hypothesized that azithromycin may have prevented deaths from respiratory infection, infectious diarrhea, and malaria in treated children and even perhaps in close contacts of treated children in the community (similar to herd immunity seen with vaccination campaigns). Of note, pneumonia, diarrhea, and malaria are leading causes of infection-related death in pediatric populations from LMICs [11]. Hence, this finding may be seen as an obvious success story; lives can be saved with a simple and relatively inexpensive MDA intervention. Interestingly, a 2-year follow-up of the multicountry study [8] focusing on Tanzanian study sites did not demonstrate mortality reduction or differences in rates of diarrhea, fever, anemia, or cough between azithromycin or placebo treatment arms [12].

Health policy makers are now reviewing evidence for azithromycin MDA to consider whether such programs should be scaled up in settings with high childhood mortality. Although we agree with the urgency of finding effective solutions to address this public health issue, in our view, utmost caution is needed before scaling up MDA with antibacterial agents beyond existing trachoma control and elimination programs. We are convinced about the



OPEN ACCESS

Citation: Bogoch II, Utzinger J, Lo NC, Andrews JR (2019) Antibacterial mass drug administration for child mortality reduction: Opportunities, concerns, and possible next steps. *PLoS Negl Trop Dis* 13(5): e0007315. <https://doi.org/10.1371/journal.pntd.0007315>

Editor: Zulfiqar A. Bhutta, The Hospital for Sick Children, CANADA

Published: May 23, 2019

Copyright: © 2019 Bogoch et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

crucially important role of anthelmintic MDA programs for large-scale morbidity control of parasitic worm (helminth) infections; however, the use of antibacterial agents poses considerably greater threats both within communities where MDA is performed and more globally.

A major concern when administering any antimicrobial agent on a mass scale, be it an antibacterial or anthelmintic drug, is the development and subsequent spread of drug resistance. As articulated by the O'Neill commission in 2016, antimicrobial resistance (AMR) is one of the biggest global health threats of our time [13]. The number of global deaths related to AMR is currently unknown because of inadequate surveillance, but contemporary projections of several hundred thousand deaths per year are gaining recognition, and these numbers are expected to rise [14]. Global efforts to reduce antimicrobial use are slow, but large-scale stewardship campaigns are taking shape with plans to both reduce consumption and facilitate the development of new antibacterial compounds [15].

Bacteria and helminths have very different mechanisms and time courses for developing resistance. Indeed, resistance appears to emerge more readily and rapidly in bacteria, which have a shorter reproductive time and can share resistance genes horizontally, facilitating their spread [16]. AMR was already detected in the 1940s, shortly after the discovery and first use of penicillin, and has developed across all classes of antibiotics [17]. As early as 1995, *Streptococcus pneumoniae* resistance was documented in children treated with a single dose of azithromycin as part of trachoma control programs, with 1.3% of swabs demonstrating resistance before MDA and 21.3% of samples demonstrating resistance up to 2 months following treatment [18]. A more recent prospective study from a trachoma control program in Niger demonstrated significantly more macrolide-resistant *S. pneumoniae* strains in children from communities treated with azithromycin twice per year (60%) compared with communities treated once per year (40%) [19]. Although other studies also documented an increase in resistant *S. pneumoniae* strains after azithromycin MDA [20], some studies did not make this observation [21, 22]. It appears that communities with a higher baseline burden of azithromycin-resistant *S. pneumoniae* are at greater risk of selecting for such resistant strains in the context of azithromycin MDA [23].

Although much of the focus in macrolide MDA is on resistant *S. pneumoniae*, enteric infections present another major threat [24, 25]. Many gastrointestinal pathogens are now resistant to commonly used antibacterial agents after years of unselective use, and effective treatment options are increasingly limited. Azithromycin is now one of the first-line oral drug choices for treatment of shigellosis, enteric fever (caused by *Salmonella* Typhi and Paratyphi A), and invasive nontyphoidal salmonellosis, all of which have seen widespread fluoroquinolone non-susceptibility following years of overuse and misuse [26]. At present, azithromycin is the only oral treatment option available for an emerging “extensively drug resistant” (XDR) *Salmonella* Typhi strain [27], which is resistant to third-generation cephalosporins [28]. There are also many other diarrhea-causing Enterobacteriaceae with emerging azithromycin resistance genes [16], and we can only expect more macrolide resistance to develop in the near future in these organisms in the face of heightened indiscriminate use.

It is conceivable that the mortality benefits of azithromycin MDA [8] will have only a narrow window before the prevalence of AMR organisms reaches levels that negate these benefits in their intended communities. Moreover, recent experience has demonstrated that resistant bacterial infections, including *Salmonella* and *Shigella*, may spread far beyond their community of origin within years [26, 29] and negatively impact communities distant from where a targeted MDA program is offered (Table 1). When macrolide AMR prevalence rises, these drugs are no longer recommended as a first-line empiric treatment for common infections like community-acquired pneumonia or infectious diarrheal illness because of the possibility of treatment failure [30]. With nonselective overuse of azithromycin, a previously effective,

Table 1. Summary of evidence for MDA campaigns targeting helminth infections versus nonselective targets of antibacterial agents.

Evidence	Helminth	Bacteria
Risk of developing AMR	Limited in human populations	Rapid emergence in human populations
Risk for subsequent AMR transmission	Limited to ecological niches of helminth	Local and global transmission over short time periods
“Off-target” effects of treatment	Relatively limited to very few helminths in the targeted MDA region	Many antibacterial agents (e.g., azithromycin) are not selective and have broad activity against gram-positive and gram-negative organisms
Efficacy in reducing local transmission of disease	Considerable	Unclear which organisms are attributed to mortality reduction; uncertain efficacy in reducing local transmission
Durability	Sustained efficacy in reduced helminth transmission over years	Lack of data

Abbreviations: AMR, antimicrobial resistance; MDA, mass drug administration.

<https://doi.org/10.1371/journal.pntd.0007315.t001>

relatively inexpensive, widely available, and well-tolerated oral therapy will no longer be useful for areas that are most in need, and there is a shrinking list of alternative antibiotics with these same attributes.

By contrast, the history of MDA campaigns against helminth infections had a different course. Indeed, MDA programs for schistosomiasis and soil-transmitted helminth infections have been in place for some two decades with praziquantel (against schistosomiasis) and albendazole or mebendazole (against soil-transmitted helminthiasis) serving as mainstays of treatment. MDA for helminth infections has also faced similar critiques. Yet, we believe that some of these critiques are misplaced, as they are largely outweighed by the benefits, as summarized in Table 1. Although the efficacy of albendazole and mebendazole varies between different species of soil-transmitted helminths [31], and certainly cure rates of schistosomiasis are lower for higher-intensity infections [32], there is no evidence for sustained anthelmintic drug resistance developing in human populations despite hundreds of millions of treatments over many years of use on a global scale. There is evidence of anthelmintic drug resistance to praziquantel developing in veterinary practice and sporadic evidence in helminths infecting humans [33]; however, clinically relevant anthelmintic resistance has not emerged on a mass scale considering the enormous breadth of schistosomiasis MDA campaigns [34]. Additionally, because of complex life cycles and ecological niches of helminths, their geographic range is far more limited, and resistance—if emergent—is unlikely to spread as swiftly as it may in bacterial infections. Numerous examples of rapid global dissemination of bacterial resistance genes underscore this point—for example, with the mobilized colistin resistance gene (*mcr-1*) [35] and the New Delhi metallo-β-lactamase-1 gene (*NDM-1*) [36] developing locally but spreading globally over a short time, both of which portend resistance to most classes of antibacterial drugs.

The judicious use of all antimicrobial agents is essential to prevent the development and spread of resistance; however, much greater caution is needed when using antibacterial compared with anthelmintic agents on a mass scale. Expanding azithromycin MDA outside of trachoma programs has the potential for widespread and sustained harm secondary to AMR development and spread. More data are needed to justify the wider use of azithromycin MDA if it is to be used for survival benefit outside of trachoma control programs, and consultation with local communities, neighboring communities, and public health stakeholders should determine if the potential benefits outweigh the risks (Table 2). For helminth infections (and malaria), modeling has been used to examine tradeoffs between reductions in transmission

Table 2. Suggested steps prior to implementing azithromycin MDA for mortality reduction outside of trachoma control programs.

Key step	Stakeholder(s)
Step 1: Identify causative pathway for mortality benefit	
<ul style="list-style-type: none"> Investigate mechanism of mortality benefit and heterogeneity by study country 	Academia
<ul style="list-style-type: none"> Estimate duration of mortality benefit with ongoing MDA efforts 	Academia
<ul style="list-style-type: none"> Define AMR risk factors to consider in programmatic decision (e.g., incidence of resistant infections) 	Academia
Step 2: Estimate risk and benefit	
<ul style="list-style-type: none"> Consider overlapping risk factors (e.g., high incidence of resistance-prone bacteria) 	Academia
<ul style="list-style-type: none"> Discussion with public health stakeholders 	Public sector; community engagement
<ul style="list-style-type: none"> Model-based analysis of tradeoff between health effects and AMR risk 	Academia
Step 3: Create distinct guidelines based on epidemiology, programmatic goals, and resource constraints on MDA implementation	
<ul style="list-style-type: none"> Guidelines for geographic zone, frequency, and duration of azithromycin MDA based on defined criteria (e.g., child mortality, AMR risk) 	World Health Organization; national public health organizations; community engagement

Abbreviations: AMR, antimicrobial resistance; MDA, mass drug administration.

<https://doi.org/10.1371/journal.pntd.0007315.t002>

and the rise of drug resistance [37]; for azithromycin MDA, in the absence of understanding the mechanisms of mortality reduction, such modeling is currently impossible. Moreover, it is challenging, if not impossible, to project the duration for which azithromycin MDA may have benefits before it is undermined by AMR.

Empirical data concerning durability of mortality reduction are needed before implementing this strategy programmatically. Until such data become available, we would recommend against azithromycin MDA in regions where AMR is common or in which azithromycin is widely used for pneumonia or gastrointestinal diseases. Instead, we suggest taking a more cautious approach and seeking other methods to reduce mortality in high-risk settings rather than expand azithromycin MDA beyond trachoma programs because of the risks of long-term harms of AMR. Should these programs expand, AMR and rigorous clinical surveillance must scale up in tandem to closely monitor for the emergence and spread of resistant pathogens, which would trigger public health responses. With the increasing global burden of highly drug-resistant bacterial infections, for which azithromycin remains a critical drug in the arsenal, the stakes are high, and the evidentiary bar for its long-term safety in widespread use should be also high.

References

1. World Health Organization. Preventive chemotherapy in human helminthiasis: coordinated use of anthelmintic drugs in control interventions: a manual for health professionals and programme managers. Geneva: World Health Organization; 2006. p. 1–62.
2. Webster JP, Molyneux DH, Hotez PJ, Fenwick A. The contribution of mass drug administration to global health: past, present and future. *Philos Trans R Soc Lond B Biol Sci.* 2014; 369 (1645): 20130434. <https://doi.org/10.1098/rstb.2013.0434> PMID: 24821920
3. Ramaiah KD, Ottesen EA. Progress and impact of 13 years of the Global Programme to Eliminate Lymphatic Filariasis on reducing the burden of filarial disease. *PLoS Negl Trop Dis.* 2014; 8 (11): e3319. <https://doi.org/10.1371/journal.pntd.0003319> PMID: 25412180

4. World Health Organization. Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and procedures. Geneva: World Health Organization; 2016 [cited 2018 Sep 2]. <http://www.who.int/onchocerciasis/resources/9789241510011/en/>.
5. World Health Organization. WHO Alliance for the Global Elimination of Trachoma by 2020: progress report on elimination of trachoma, 2014–2016. *Wkly Epidemiol Rec*. 2017; 92 (26): 359–68.
6. Lai YS, Biedermann P, Ekpo UF, Garba A, Mathieu E, Midzi N, et al. Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis. *Lancet Infect Dis*. 2015; 15 (8): 927–40. [https://doi.org/10.1016/S1473-3099\(15\)00066-3](https://doi.org/10.1016/S1473-3099(15)00066-3) PMID: 26004859
7. Bronzan RN, Dorkenoo AM, Agbo YM, Halatoko W, Layibo Y, Adjeloh P, et al. Impact of community-based integrated mass drug administration on schistosomiasis and soil-transmitted helminth prevalence in Togo. *PLoS Negl Trop Dis*. 2018; 12 (8): e0006551. <https://doi.org/10.1371/journal.pntd.0006551> PMID: 30125274
8. Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, et al. Azithromycin to reduce childhood mortality in sub-Saharan Africa. *N Engl J Med*. 2018; 378 (17): 1583–92. <https://doi.org/10.1056/NEJMoa1715474> PMID: 29694816
9. Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. *JAMA*. 2009; 302 (9): 962–8. <https://doi.org/10.1001/jama.2009.1266> PMID: 19724043
10. Keenan JD, Ayele B, Gebre T, Zerihun M, Zhou Z, House JI, et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. *Clin Infect Dis*. 2011; 52 (7): 883–8. <https://doi.org/10.1093/cid/cir069> PMID: 21427395
11. Dicker D. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018; 392 (10159): 1684–735. [https://doi.org/10.1016/S0140-6736\(18\)31891-9](https://doi.org/10.1016/S0140-6736(18)31891-9)
12. West SK, Bloch E, Weaver J, Munoz B, Mrango Z, Kasubi M, et al. Morbidity in a longitudinal cohort of children residing in villages randomized to 6 monthly treatment with azithromycin versus placebo. *Clin Infect Dis*. 2019. <https://doi.org/10.1093/cid/ciz269> Epub 2019 Apr 5. PMID: 30950493
13. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations. 2016. https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf. [cited 2019 May 2].
14. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance—the need for global solutions. *Lancet Infect Dis*. 2013; 13 (12): 1057–98. [https://doi.org/10.1016/S1473-3099\(13\)70318-9](https://doi.org/10.1016/S1473-3099(13)70318-9)
15. World Health Organization. Global Action Plan on Antimicrobial Resistance. Geneva: World Health Organization; 2015 [cited 2018 Sep 2]. <http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/>.
16. Gomes C, Martinez-Puchol S, Palma N, Horna G, Ruiz-Roldan L, Pons MJ, et al. Macrolide resistance mechanisms in Enterobacteriaceae: focus on azithromycin. *Crit Rev Microbiol*. 2017; 43 (1): 1–30. <https://doi.org/10.3109/1040841X.2015.1136261> PMID: 27786586
17. Plough HH. Penicillin resistance of *Staphylococcus aureus* and its clinical implications. *Am J Clin Pathol*. 1945; 15: 446–51. PMID: 21005048
18. Leach AJ, Shelby-James TM, Mayo M, Gratten M, Laming AC, Currie BJ, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of *Streptococcus pneumoniae*. *Clin Infect Dis*. 1997; 24 (3): 356–62. PMID: 9114185
19. Keenan JD, Chin SA, Amza A, Kadri B, Nassirou B, Cevallos V, et al. The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster-randomized trial. *Clin Infect Dis*. 2018; 67: 1736–42. <https://doi.org/10.1093/cid/ciy339> PMID: 29897440
20. Coles CL, Mabula K, Seidman JC, Levens J, Mkocho H, Munoz B, et al. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant *Streptococcus pneumoniae* carriage in young children 6 months after treatment. *Clin Infect Dis*. 2013; 56 (11): 1519–26. <https://doi.org/10.1093/cid/cit137> PMID: 23487375
21. Fry AM, Jha HC, Lietman TM, Chaudhary JSP, Bhatta RC, Elliott J, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. *Clin Infect Dis*. 2002; 35 (4): 395–402. <https://doi.org/10.1086/341414> PMID: 12145722
22. Batt SL, Charalambous BM, Solomon AW, Knirsch C, Massae PA, Safari S, et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant *Streptococcus pneumoniae*. *Antimicrob Agents Chemother*. 2003; 47 (9): 2765–9. <https://doi.org/10.1128/AAC.47.9.2765-2769.2003> PMID: 12936971

23. O'Brien KS, Emerson P, Hooper PJ, Reingold AL, Dennis EG, Keenan JD, et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. *Lancet Infect Dis*. 2019; 19: e14–e25. [https://doi.org/10.1016/S1473-3099\(18\)30444-4](https://doi.org/10.1016/S1473-3099(18)30444-4) PMID: 30292480
24. Wang H, Liddell CA, Coates MM, Mooney MD, Levitz CE, Schumacher AE, et al. Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2014; 384 (9947): 957–79. [https://doi.org/10.1016/S0140-6736\(14\)60497-9](https://doi.org/10.1016/S0140-6736(14)60497-9)
25. Kyu HH, Pinho C, Wagner JA, Brown JC, Bertozzi-Villa A, Charlson FJ, et al. Global and national burden of diseases and injuries among children and adolescents between 1990 and 2013: findings from the Global Burden of Disease 2013 study. *JAMA Pediatr*. 2016; 170 (3): 267–87. <https://doi.org/10.1001/jamapediatrics.2015.4276> PMID: 26810619
26. Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of *Salmonella Typhi* identifies inter- and intracontinental transmission events. *Nat Genet*. 2015; 47 (6): 632–9. <https://doi.org/10.1038/ng.3281> PMID: 25961941
27. Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of an extensively drug-resistant *Salmonella enterica* serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. *mBio*. 2018; 9 (1): e00105–18. <https://doi.org/10.1128/mBio.00105-18> PMID: 29463654
28. Vlieghe ER, Phe T, De Smet B, Veng CH, Kham C, Bertrand S, et al. Azithromycin and ciprofloxacin resistance in *Salmonella* bloodstream infections in Cambodian adults. *PLoS Negl Trop Dis*. 2012; 6 (12): e1933. <https://doi.org/10.1371/journal.pntd.0001933> PMID: 23272255
29. Chung The H, Rabaa MA, Pham Thanh D, De Lappe N, Cormican M, Valcanis M, et al. South Asia as a reservoir for the global spread of ciprofloxacin-resistant *Shigella sonnei*: a cross-sectional study. *PLoS Med*. 2016; 13 (8): e1002055. <https://doi.org/10.1371/journal.pmed.1002055> PMID: 27483136
30. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007; 44 (Suppl 2): S27–S72. <https://doi.org/10.1086/511159> PMID: 17278083
31. Moser W, Schindler C, Keiser J. Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis. *BMJ*. 2017; 358: j4307. <https://doi.org/10.1136/bmj.j4307> PMID: 28947636
32. Webster BL, Diaw OT, Seye MM, Faye DS, Stothard JR, Sousa-Figueiredo JC, et al. Praziquantel treatment of school children from single and mixed infection foci of intestinal and urogenital schistosomiasis along the Senegal River Basin: monitoring treatment success and re-infection patterns. *Acta Trop*. 2013; 128 (2): 292–302. <https://doi.org/10.1016/j.actatropica.2012.09.010> PMID: 23022016
33. Geerts S, Gryseels B. Drug resistance in human helminths: current situation and lessons from livestock. *Clin Microbiol Rev*. 2000; 13 (2): 207–22. PMID: 10755998
34. Bergquist R, Utzinger J, Keiser J. Controlling schistosomiasis with praziquantel: how much longer without a viable alternative? *Infect Dis Poverty*. 2017; 6: 74. <https://doi.org/10.1186/s40249-017-0286-2> PMID: 28351414
35. Wang R, van Dorp L, Shaw LP, Bradley P, Wang Q, Wang X, et al. The global distribution and spread of the mobilized colistin resistance gene mcr-1. *Nature Commun*. 2018; 9 (1): 1179. <https://doi.org/10.1038/s41467-018-03205-z> PMID: 29563494
36. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis*. 2011; 17 (10): 1791–8. <https://doi.org/10.3201/eid1710.110655> PMID: 22000347
37. White NJ. Does antimalarial mass drug administration increase or decrease the risk of resistance? *Lancet Infect Dis*. 2017; 17 (1): e15–e20. [https://doi.org/10.1016/S1473-3099\(16\)30269-9](https://doi.org/10.1016/S1473-3099(16)30269-9) PMID: 27839929